Silk develops a natural chemistry platform built on patented Liquid Silk technology that is biodegradable and biocompatible. The company positions Liquid Silk as an alternative to petrochemicals found in everyday consumer goods. Its cross-industry applications include apparel—where Silk is teaming with fashion brands to replace synthetic finishing chemicals at commercial scale—and clinical-grade, minimal-ingredient skincare. Founded in 2013 by Drs. Gregory Altman and Rebecca Lacouture, Silk is based in Boston, Massachusetts. The company plans to use the Series B proceeds to launch its safe chemistry into the fashion and textile industry and to scale up production to meet global demand. Financially, Silk closed a $30m Series B in October 2018.

Total raised

$30M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2018